Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer

G. Falkson, R. S. Gelman, R. Dreicer, D. C. Tormey, A. S. Alberts, M. A. Coccia-Portugal, D. Rushing, J. M. Bennett

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

One thousand four hundred sixty patients with 2,590 patient-years of follow-up were treated on 15 protocols for metastatic breast cancer with dibromodulcitol (mitolactol; DBD)-containing regimens since 1976. Twenty-three patients developed myelodysplastic syndrome (MDS) and/or acute nonlymphocytic leukemia (ANLL). The overall risk of developing MDS or ANLL per person is 1.6%. In patients who had received more than 16,000 mg of DBD the risk per person is 6%, and in the high-dose subsets of patients who received no prior radiation or alkylator therapy, it is 7.9%. The risk per person increases to a maximum by 30 to 36 months (5.3%). The hgh risk was seen despite a study population of metastatic breast cancer patients with a median survival of 16 months. This analysis strongly suggests that BDB is one of the most potent of the reported leukemogenic-inducing agents. Further use of this drug in both the adjuvant and metastatic situation should be reconsidered.

Original languageEnglish (US)
Pages (from-to)1252-1259
Number of pages8
JournalJournal of Clinical Oncology
Volume7
Issue number9
StatePublished - 1989
Externally publishedYes

Fingerprint

Mitolactol
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Breast Neoplasms
Therapeutics
Alkylating Agents
Radiation
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Falkson, G., Gelman, R. S., Dreicer, R., Tormey, D. C., Alberts, A. S., Coccia-Portugal, M. A., ... Bennett, J. M. (1989). Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. Journal of Clinical Oncology, 7(9), 1252-1259.

Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. / Falkson, G.; Gelman, R. S.; Dreicer, R.; Tormey, D. C.; Alberts, A. S.; Coccia-Portugal, M. A.; Rushing, D.; Bennett, J. M.

In: Journal of Clinical Oncology, Vol. 7, No. 9, 1989, p. 1252-1259.

Research output: Contribution to journalArticle

Falkson, G, Gelman, RS, Dreicer, R, Tormey, DC, Alberts, AS, Coccia-Portugal, MA, Rushing, D & Bennett, JM 1989, 'Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer', Journal of Clinical Oncology, vol. 7, no. 9, pp. 1252-1259.
Falkson G, Gelman RS, Dreicer R, Tormey DC, Alberts AS, Coccia-Portugal MA et al. Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. Journal of Clinical Oncology. 1989;7(9):1252-1259.
Falkson, G. ; Gelman, R. S. ; Dreicer, R. ; Tormey, D. C. ; Alberts, A. S. ; Coccia-Portugal, M. A. ; Rushing, D. ; Bennett, J. M. / Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. In: Journal of Clinical Oncology. 1989 ; Vol. 7, No. 9. pp. 1252-1259.
@article{b9b25838d77440dca7c0aa94e7447c3a,
title = "Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer",
abstract = "One thousand four hundred sixty patients with 2,590 patient-years of follow-up were treated on 15 protocols for metastatic breast cancer with dibromodulcitol (mitolactol; DBD)-containing regimens since 1976. Twenty-three patients developed myelodysplastic syndrome (MDS) and/or acute nonlymphocytic leukemia (ANLL). The overall risk of developing MDS or ANLL per person is 1.6{\%}. In patients who had received more than 16,000 mg of DBD the risk per person is 6{\%}, and in the high-dose subsets of patients who received no prior radiation or alkylator therapy, it is 7.9{\%}. The risk per person increases to a maximum by 30 to 36 months (5.3{\%}). The hgh risk was seen despite a study population of metastatic breast cancer patients with a median survival of 16 months. This analysis strongly suggests that BDB is one of the most potent of the reported leukemogenic-inducing agents. Further use of this drug in both the adjuvant and metastatic situation should be reconsidered.",
author = "G. Falkson and Gelman, {R. S.} and R. Dreicer and Tormey, {D. C.} and Alberts, {A. S.} and Coccia-Portugal, {M. A.} and D. Rushing and Bennett, {J. M.}",
year = "1989",
language = "English (US)",
volume = "7",
pages = "1252--1259",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer

AU - Falkson, G.

AU - Gelman, R. S.

AU - Dreicer, R.

AU - Tormey, D. C.

AU - Alberts, A. S.

AU - Coccia-Portugal, M. A.

AU - Rushing, D.

AU - Bennett, J. M.

PY - 1989

Y1 - 1989

N2 - One thousand four hundred sixty patients with 2,590 patient-years of follow-up were treated on 15 protocols for metastatic breast cancer with dibromodulcitol (mitolactol; DBD)-containing regimens since 1976. Twenty-three patients developed myelodysplastic syndrome (MDS) and/or acute nonlymphocytic leukemia (ANLL). The overall risk of developing MDS or ANLL per person is 1.6%. In patients who had received more than 16,000 mg of DBD the risk per person is 6%, and in the high-dose subsets of patients who received no prior radiation or alkylator therapy, it is 7.9%. The risk per person increases to a maximum by 30 to 36 months (5.3%). The hgh risk was seen despite a study population of metastatic breast cancer patients with a median survival of 16 months. This analysis strongly suggests that BDB is one of the most potent of the reported leukemogenic-inducing agents. Further use of this drug in both the adjuvant and metastatic situation should be reconsidered.

AB - One thousand four hundred sixty patients with 2,590 patient-years of follow-up were treated on 15 protocols for metastatic breast cancer with dibromodulcitol (mitolactol; DBD)-containing regimens since 1976. Twenty-three patients developed myelodysplastic syndrome (MDS) and/or acute nonlymphocytic leukemia (ANLL). The overall risk of developing MDS or ANLL per person is 1.6%. In patients who had received more than 16,000 mg of DBD the risk per person is 6%, and in the high-dose subsets of patients who received no prior radiation or alkylator therapy, it is 7.9%. The risk per person increases to a maximum by 30 to 36 months (5.3%). The hgh risk was seen despite a study population of metastatic breast cancer patients with a median survival of 16 months. This analysis strongly suggests that BDB is one of the most potent of the reported leukemogenic-inducing agents. Further use of this drug in both the adjuvant and metastatic situation should be reconsidered.

UR - http://www.scopus.com/inward/record.url?scp=0024432021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024432021&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 1252

EP - 1259

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -